Company Profile For Amgen Inc.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care, nephrology and inflammation. Its principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept). Aranesp and EPOGEN stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (ESAs). On January 4, 2008, the Company completed the acquisition of Dompe Biotec, S.p.A.

BRIEF: For the fiscal year ended 31 December 2009, Amgen, Inc.'s revenues decreased 2% to $14.64B. Net income increased 14% to $4.61B. Revenues reflect a decrease in income from product sales and lower other revenue. Net income was offset by decreased cost of sales due to lower excess inventory write off, a decrease in research & development expenses, lower other charges and lower interest & other income, net.